Avastin Approval May Be Delayed

Genentech Inc. (DNA) impressed with second quarter earnings that soared to 49 cents per share from 27 cents per share a year earlier. However, the stock price dropped $3.08 to close at $80.98 after announcing that approval of the company's Avastin colon cancer medication to treat breast cancer may be delayed.